
  
    
      
        Ross_NNP McKinney_NNP 's_POS Viewpoint_NN :_: Universities_NNS Should_MD Be_VB Allowed_NNP ,_, Provided_VBN the_DT Trial_NNP Is_VBZ
        Approved_NNP by_IN an_DT External_NNP Review_NNP Board_NNP
        One_CD of_IN the_DT principal_JJ missions_NNS of_IN an_DT academic_JJ health_NN center_NN is_VBZ to_TO advance_VB the_DT
        understanding_NN and_CC treatment_NN of_IN disease_NN through_IN clinical_JJ research_NN ._. In_IN this_DT pursuit_NN ,_, there_EX is_VBZ
        a_DT need_NN for_IN checks_NNS and_CC balances_NNS ._. When_WRB Jesse_NNP Gelsinger_NNP ,_, a_DT relatively_RB healthy_JJ young_JJ adult_NN ,_,
        died_VBD in_IN Philadelphia_NNP during_IN a_DT clinical_JJ trial_NN of_IN a_DT novel_NN adenovirus-based_JJ genetic_JJ therapy_NN
        for_IN ornithine_NN transcarbamylase_NN deficiency_NN ,_, it_PRP was_VBD a_DT tragedy_NN [_NN 1_CD ]_NN ._. In_IN retrospect_NN ,_, there_EX were_VBD
        many_JJ clues_NNS that_IN there_EX were_VBD problems_NNS with_IN the_DT adenovirus_JJ vector_NN ,_, clues_NNS that_IN neither_DT the_DT
        investigator_NN nor_CC the_DT institution_NN pursued_VBN ._.
        Attorney_NNP Alan_NNP Milstein_NNP made_VBD the_DT case_NN that_IN the_DT investigator_NN and_CC institution_NN were_VBD both_DT
        blinded_JJ to_TO these_DT problems_NNS by_IN their_PRP$ heavy_JJ financial_JJ investment_NN in_IN the_DT technology_NN ,_, an_DT
        investment_NN worth_JJ millions_NNS of_IN dollars_NNS [_NN 2_CD ]_NN ._. Though_IN the_DT legal_JJ case_NN was_VBD settled_VBN out_IN of_IN court_NN ,_,
        it_PRP created_VBD a_DT de_IN facto_FW standard_JJ that_IN institutions_NNS with_IN commercial_JJ rights_NNS in_IN a_DT new_JJ drug_NN or_CC
        technology_NN should_MD not_RB be_VB allowed_VBN to_TO pursue_VB clinical_JJ trials_NNS involving_VBG that_IN new_JJ technology_NN ._. I_PRP
        do_VBP not_RB believe_VB that_IN such_JJ a_DT blanket_NN prohibition_NN is_VBZ necessary_JJ ._.
        At_IN its_PRP$ core_NN ,_, the_DT issue_NN revolves_VBZ around_IN conflicts_NNS of_IN interest_NN ._. In_IN clinical_JJ research_NN ,_, the_DT
        investigator_NN should_MD be_VB primarily_RB an_DT advocate_NN for_IN the_DT patient_NN or_CC volunteer_NN ._. The_DT core_NN reason_NN
        to_TO perform_VB clinical_JJ research_NN is_VBZ to_TO create_VB generalizable_JJ knowledge_NN about_IN a_DT therapy_NN ,_, patient_NN
        population_NN ,_, or_CC a_DT disease_NN process_NN with_IN the_DT long-term_JJ intent_NN of_IN improving_VBG human_JJ health_NN ._. The_DT
        interests_NNS of_IN the_DT patient_NN and_CC investigator_NN should_MD be_VB fully_RB aligned_VBN ._. However_RB ,_, most_JJS physicians_NNS
        in_IN clinical_JJ research_NN have_VBP other_JJ ,_, more_RBR personal_JJ motivations_NNS ,_, intermixed_VBD with_IN the_DT desire_NN for_IN
        progress_NN ._. Successful_JJ research_NN projects_NNS can_MD lead_VB to_TO publications_NNS ,_, promotions_NNS ,_, grant_VB
        renewals_NNS ,_, and_CC per_IN case_NN clinical_JJ trial_NN enrollment_NN fees_NNS ._. Some_DT investigators_NNS have_VBP intellectual_JJ
        property_NN rights_NNS that_WDT may_MD have_VB very_RB substantial_JJ financial_JJ value_NN if_IN the_DT drug_NN or_CC device_NN
        reaches_VBZ the_DT level_NN of_IN approval_NN by_IN the_DT United_NNP States_NNPS Food_NNP and_CC Drug_NNP Administration_NNP ._. These_DT
        investigators_NNS stand_VBP to_TO gain_VB personally_RB if_IN the_DT clinical_JJ trial_NN is_VBZ successful_JJ ,_, a_DT situation_NN
        that_WDT has_VBZ the_DT potential_NN to_TO distort_VB the_DT investigator_NN 's_POS objectivity_NN ,_, and_CC may_MD lead_VB to_TO a_DT less_RBR
        honest_JJ relationship_NN with_IN study_NN volunteers_NNS ._.
        In_IN order_NN to_TO ensure_VB that_IN investigators_NNS are_VBP honest_JJ with_IN potential_JJ research_NN volunteers_NNS ,_, the_DT
        system_NN of_IN institutional_JJ review_NN boards_NNS (_( IRBs_NNP )_) evolved_VBD ._. The_DT IRB_NNP approves_VBZ the_DT informed_VBN consent_NN
        document_NN ,_, which_WDT should_MD describe_VB the_DT clinical_JJ experiment_NN in_IN a_DT clear_JJ and_CC dispassionate_NN way_NN to_TO
        patients_NNS and_CC their_PRP$ families_NNS ._. IRBs_NNP are_VBP largely_RB made_VBN up_RP of_IN faculty_NN and_CC staff_NN from_IN the_DT
        institution_NN ,_, although_IN there_EX are_VBP also_RB public_JJ members_NNS and_CC nonscientists_NNS on_IN most_JJS IRB_NNP panels_NNS ._.
        The_DT IRB_NNP must_MD remain_VB autonomous_JJ and_CC be_VB able_JJ to_TO hold_VB up_RP or_CC stop_VB an_DT investigation_NN ._. There_EX is_VBZ an_DT
        obligation_NN that_IN the_DT IRB_NNP first_JJ and_CC foremost_RB think_VBP about_IN patient_NN rights_NNS and_CC safety_NN ._.
        The_DT passage_NN of_IN the_DT Bayh–_NNP Dole_NNP Act_NNP in_IN 1980_CD enabled_VBD universities_NNS to_TO license_VB inventions_NNS for_IN
        commercial_JJ development_NN [_NN 3_CD ]_NN ._. The_DT closer_JJR to_TO Food_NNP and_CC Drug_NNP Administration_NNP approval_NN the_DT drug_NN or_CC
        technology_NN is_VBZ at_IN the_DT time_NN of_IN licensure_NN ,_, the_DT more_RBR valuable_JJ it_PRP becomes_VBZ ._. Therefore_RB ,_,
        universities_NNS have_VBP an_DT incentive_NN to_TO advance_VB the_DT clinical_JJ development_NN of_IN inventions_NNS by_IN their_PRP$
        faculty_NN ._. In_IN this_DT regard_NN ,_, they_PRP are_VBP very_RB much_RB like_IN corporate_JJ sponsors_NNS of_IN research_NN ,_, subject_JJ to_TO
        the_DT same_JJ Food_NNP and_CC Drug_NNP Administration_NNP oversight_NN as_IN corporations_NNS ._.
        In_IN terms_NNS of_IN performing_VBG clinical_JJ trials_NNS using_VBG new_JJ technologies_NNS in_IN which_WDT it_PRP has_VBZ a_DT
        financial_JJ interest_NN ,_, how_WRB is_VBZ a_DT university_NN different_JJ from_IN a_DT corporate_JJ sponsor_NN ?_. In_IN regard_NN to_TO
        patient_NN safety_NN ,_, one_CD primary_JJ distinction_NN rests_VBZ with_IN the_DT IRB_NNP ._. The_DT corporate_JJ sponsor_NN will_MD
        present_VB the_DT research_NN protocol_NN to_TO an_DT independent_JJ commercial_JJ IRB_NNP ,_, the_DT university_NN to_TO its_PRP$ own_JJ
        IRB_NNP ._. Yet_RB in_IN both_DT cases_NNS ,_, there_EX are_VBP potential_JJ conflicts_NNS of_IN interest_NN ._. The_DT university_NN IRB_NNP
        members_NNS will_MD have_VB a_DT conflict_NN of_IN interest_NN between_IN the_DT investments_NNS of_IN their_PRP$ employer_NN and_CC the_DT
        rights_NNS of_IN the_DT research_NN volunteers_NNS ._. Independent_NNP commercial_JJ IRBs_NNP depend_VB on_IN pleasing_VBG corporate_JJ
        customers_NNS for_IN their_PRP$ continued_JJ existence_NN ,_, and_CC there_EX is_VBZ an_DT unstated_JJ expectation_NN that_IN they_PRP
        will_MD both_DT be_VB fast_RB and_CC produce_VB rulings_NNS consistent_JJ with_IN corporate_JJ expectations_NNS (_( which_WDT in_IN most_JJS
        cases_NNS include_VBP a_DT desire_NN to_TO do_VB the_DT research_NN ethically_RB )_) ._.
        At_IN the_DT university_NN level_NN a_DT logical_JJ and_CC conservative_JJ solution_NN to_TO the_DT problem_NN of_IN
        institutional_JJ conflicts_NNS is_VBZ to_TO require_VB that_IN an_DT IRB_NNP from_IN outside_IN the_DT institution_NN become_VBP the_DT
        IRB_NNP of_IN record_NN when_WRB such_JJ a_DT conflict_NN arises_VBZ ._. This_DT external_JJ IRB_NNP could_MD be_VB either_CC an_DT independent_JJ
        commercial_JJ IRB_NNP or_CC one_CD of_IN another_DT university_NN ._. The_DT key_NN is_VBZ to_TO grant_VB the_DT IRB_NNP independence_NN and_CC
        the_DT authority_NN to_TO provide_VB real_JJ oversight_NN ._.
        There_EX are_VBP other_JJ elements_NNS of_IN conflicts_NNS of_IN interest_NN that_WDT need_VBP to_TO be_VB considered_VBN when_WRB the_DT
        institution_NN has_VBZ a_DT commercial_JJ interest_NN ,_, but_CC most_JJS have_VBP more_JJR to_TO do_VB with_IN the_DT management_NN of_IN
        personal_JJ conflicts_NNS than_IN institutional_JJ conflicts_NNS ._. The_DT institution_NN needs_VBZ to_TO assure_VB the_DT
        presence_NN of_IN an_DT independent_JJ data_NN safety_NN monitoring_VBG board_NN ,_, thorough_JJ audits_NN of_IN good_JJ clinical_JJ
        practice_NN ,_, and_CC a_DT publications_NNS committee_NN that_WDT will_MD ensure_VB submission_NN of_IN all_DT meaningful_JJ study_NN
        results_NNS ,_, whether_IN positive_JJ ,_, negative_JJ ,_, or_CC neutral_JJ ._. Anyone_NN subjectively_RB evaluating_VBG patient_NN
        data_NNS should_MD be_VB as_IN free_JJ of_IN conflicts_NNS as_IN possible_JJ ._. These_DT steps_NNS can_MD be_VB formulaically_RB required_VBN ,_,
        which_WDT should_MD allow_VB for_IN performance_NN of_IN clinical_JJ research_NN despite_IN the_DT presence_NN of_IN
        institutional_JJ commercial_JJ interests_NNS ._.
      
      
        David_NNP Korn_NNP 's_POS Viewpoint_NN :_: Academic_NNP Biomedical_NNP Research_NNP Must_MD Be_VB Free_NNP from_IN the_DT Taint_NNP of_IN
        Financial_NNP Compromise_NNP
        United_NNP States_NNPS research_NN universities_NNS ,_, and_CC especially_RB their_PRP$ academic_JJ medical_JJ centers_NNS ,_, have_VBP
        greatly_RB benefited_VBN from_IN their_PRP$ uniquely_RB privileged_JJ status_NN in_IN our_PRP$ society_NN ._. That_DT status_NN is_VBZ
        rooted_VBN in_IN public_JJ confidence_NN and_CC trust_NN that_IN these_DT institutions_NNS and_CC their_PRP$ faculties_NNS will_MD be_VB
        independent_JJ and_CC impartial_JJ in_IN fulfilling_VBG both_DT their_PRP$ academic_JJ mission_NN to_TO create_VB ,_, transmit_VB ,_,
        and_CC preserve_VB knowledge_NN ,_, and_CC their_PRP$ duty_NN to_TO the_DT general_JJ society_NN to_TO serve_VB as_IN credible_JJ ,_,
        trustworthy_NN arbiters_NNS of_IN knowledge_NN ._. One_CD important_JJ mark_NN of_IN this_DT status_NN has_VBZ been_VBN the_DT
        remarkably_RB consistent_JJ generosity_NN of_IN public_JJ support_NN for_IN biomedical_JJ research_NN ._. Another_DT has_VBZ
        been_VBN the_DT noteworthy_JJ deference_NN of_IN the_DT federal_JJ government_NN to_TO university_NN autonomy_NN ,_, and_CC the_DT
        light_JJ hand_NN with_IN which_WDT the_DT sponsoring_VBG agencies_NNS historically_RB have_VBP overseen_VBN the_DT conduct_NN of_IN
        university_NN research_NN ._.
        When_WRB federal_JJ interposition_NN occurred_VBD ,_, it_PRP typically_RB responded_VBD to_TO widely_RB publicized_VBN
        episodes_NNS of_IN research_NN misconduct_NN ,_, sometimes_RB intertwined_VBN with_IN egregious_JJ financial_JJ self_NN
        interests_NNS of_IN investigators_NNS ;_: these_DT episodes_NNS legitimately_RB questioned_VBD the_DT effectiveness_NN of_IN
        institutional_JJ oversight_NN ._. Nevertheless_RB ,_, regulations_NNS consistently_RB focused_VBN more_RBR on_IN defining_VBG
        the_DT metes_NNS and_CC bounds_NNS of_IN the_DT permissible_NN than_IN on_IN prescriptive_JJ mandates_NNS ,_, and_CC their_PRP$
        implementation_NN was_VBD effected_JJ largely_RB through_IN the_DT mechanism_NN of_IN “ assurances_NNS” —_NN commitments_NNS that_IN
        institutions_NNS would_MD faithfully_RB safeguard_VB the_DT specified_VBN perimeters_NNS of_IN acceptable_JJ conduct_NN ._.
        Awardee_NNP institutions_NNS thus_RB bear_VBP primary_JJ responsibility_NN for_IN assuring_VBG the_DT credibility_NN and_CC
        integrity_NN of_IN federally_RB sponsored_VBN research_NN ._. Public_JJ confidence_NN in_IN the_DT trustworthiness_NNS of_IN
        these_DT institutions_NNS is_VBZ critical_JJ ,_, and_CC yet_RB nowhere_RB is_VBZ it_PRP more_RBR fragile_JJ than_IN in_IN biomedical_JJ
        research_NN involving_VBG human_JJ participants_NNS ._. That_DT confidence_NN eroded_VBN in_IN the_DT 1980_CD s_VBZ and_CC 1990_CD s_VBZ
        because_IN of_IN reports_NNS of_IN scientific_JJ misconduct_NN and_CC of_IN individual_JJ and_CC institutional_JJ financial_JJ
        self_NN interests_NNS in_IN clinical_JJ trials_NNS ._. Scathing_NNP reports_NNS from_IN federal_JJ oversight_NN agencies_NNS and_CC
        angry_JJ congressional_JJ hearings_NNS questioned_VBD whether_IN financially_RB self-interested_JJ institutions_NNS
        could_MD any_RB longer_RBR be_VB trusted_VBN to_TO guard_VB the_DT welfare_NN of_IN research_NN participants_NNS or_CC the_DT integrity_NN
        of_IN clinical_JJ research_NN ._.
        In_IN 2001_CD ,_, the_DT Association_NNP of_IN American_NNP Medical_NNP Colleges_NNS convened_VBD a_DT task_NN force_NN to_TO examine_VB
        and_CC make_VB recommendations_NNS on_IN individual_JJ and_CC institutional_JJ financial_JJ self_NN interests_NNS in_IN
        clinical_JJ research_NN ._. The_DT task_NN force_NN began_VBD by_IN recognizing_VBG four_CD important_JJ trends_NNS over_IN the_DT past_JJ
        three_CD decades_NNS ._. First_LS ,_, the_DT nature_NN and_CC culture_NN of_IN academic_JJ biomedical_JJ research_NN have_VBP changed_VBN ,_,
        bringing_VBG the_DT potential_NN of_IN commercial_JJ relevance_NN even_RB to_TO the_DT most_RBS fundamental_JJ of_IN scientific_JJ
        discoveries_NNS ._. Second_JJ ,_, there_EX has_VBZ been_VBN enormous_JJ growth_NN in_IN the_DT extent_NN and_CC depth_NN of_IN interactions_NNS
        between_IN research_NN universities_NNS and_CC industry_NN ,_, especially_RB in_IN biomedicine_NN ._. Third_NNP ,_, the_DT public_NN
        has_VBZ become_VBN increasingly_RB impatient_JJ that_IN its_PRP$ extraordinary_JJ investments_NNS in_IN research_NN yield_NN more_RBR
        effective_JJ disease_NN preventions_NNS and_CC therapies_NNS ._. Fourth_JJ ,_, the_DT involvement_NN of_IN academic_JJ
        researchers_NNS in_IN the_DT translation_NN of_IN their_PRP$ discoveries_NNS has_VBZ been_VBN essential_JJ in_IN bringing_VBG those_DT
        discoveries_NNS to_TO market_VB and_CC to_TO the_DT benefit_NN of_IN public_JJ health_NN ._.
        But_CC the_DT task_NN force_NN ,_, in_IN its_PRP$ two_CD reports_NNS ,_, asserted_VBD that_IN both_DT individual_JJ and_CC institutional_JJ
        financial_JJ conflicts_NNS of_IN interest_NN in_IN clinical_JJ research_NN could_MD be_VB problematic_JJ [_NN 4_CD ,_, 5_CD ]_NN ._. It_PRP
        recommended_VBD urgent_JJ and_CC substantial_JJ refinement_NN and_CC strengthening_NN of_IN institutional_JJ policies_NNS
        and_CC practices_NNS for_IN monitoring_VBG ,_, managing_VBG ,_, and—when_NN necessary—extinguishing_VBG such_JJ
        conflicts_NNS ._.
        Both_DT reports_NNS rest_VBP on_IN a_DT common_JJ set_NN of_IN core_NN principles_NNS ._. The_DT most_RBS important_JJ is_VBZ that_IN
        institutions_NNS should_MD regard_VB all_DT significant_JJ financial_JJ interests_NNS in_IN research_NN involving_VBG human_JJ
        participants_NNS as_RB potentially_RB problematic_JJ ._. Where_WRB such_JJ interests_NNS exist_VBP ,_, there_EX should_MD be_VB a_DT
        rebuttable_JJ presumption_NN that_IN the_DT concerned_VBN individual_NN or_CC institution_NN should_MD not_RB conduct_VB the_DT
        research_NN ,_, absent_JJ compelling_JJ circumstances_NNS ._. Importantly_NNP ,_, the_DT task_NN force_NN ,_, after_IN intense_JJ
        debate_NN ,_, rejected_VBD categorical_JJ prohibitions_NNS lest_IN they_PRP unintentionally_RB impede_VB the_DT translation_NN
        of_IN research_NN discoveries_NNS into_IN tangible_JJ public_JJ benefits_NNS ._.
        The_DT task_NN force_NN acknowledged_VBD that_IN the_DT issue_NN of_IN institutional_JJ financial_JJ self_NN interests_NNS is_VBZ
        extraordinarily_RB complex_JJ and_CC sensitive_JJ ,_, since_IN it_PRP touches_NNS the_DT very_JJ core_NN of_IN institutional_JJ
        autonomy_NN ._. But_CC the_DT fact_NN that_IN an_DT institution_NN has_VBZ a_DT financial_JJ interest_NN per_IN se_FW should_MD raise_VB a_DT
        strong_JJ presumption_NN against_IN its_PRP$ participation_NN in_IN the_DT clinical_JJ testing_NN of_IN that_DT product_NN ._.
        Public_JJ accountability_NN and_CC scientific_JJ integrity_NN require_VB that_IN all_DT research_NN results_NNS emanating_VBG
        from_IN academic_JJ medicine_NN be_VB as_RB free_JJ as_IN possible_JJ from_IN the_DT taint_NN of_IN financial_JJ compromise_NN ._.
        Adding_VBG human_JJ participants_NNS to_TO the_DT research_NN mix_NN should_MD raise_VB the_DT barrier_NN to_TO the_DT highest_JJS level_NN
        and_CC require_VB compelling_JJ justification_NN for_IN any_DT participation_NN by_IN a_DT financially_RB self-interested_JJ
        institution_NN ._.
        The_DT task_NN force_NN did_VBD not_RB define_VB “ compelling_JJ ,_,” believing_VBG that_IN each_DT institution_NN should_MD make_VB
        that_DT determination_NN based_VBN on_IN disinterested_JJ scrutiny_NN of_IN the_DT facts_NNS and_CC circumstances_NNS of_IN each_DT
        case_NN ._. For_IN example_NN ,_, there_EX may_MD exist_VB in_IN a_DT given_VBN institution_NN a_DT unique_JJ capability_NN ,_, without_IN
        which_WDT the_DT proposed_VBN research_NN involving_VBG human_JJ participants_NNS could_MD not_RB be_VB conducted_VBN as_RB
        effectively_RB or_CC safely_RB ,_, or_CC at_IN all_DT ._. In_IN these_DT instances_NNS ,_, the_DT public_NN and_CC science_NN deserve_VBP access_NN
        to_TO that_DT capability_NN ,_, provided_VBD the_DT necessary_JJ safeguards_NNS are_VBP put_VBN in_IN place_NN to_TO mediate_VB the_DT
        conflicting_JJ interests_NNS ._. In_IN all_DT such_JJ instances_NNS ,_, protection_NN of_IN scientific_JJ integrity_NN and_CC the_DT
        welfare_NN of_IN research_NN participants_NNS must_MD remain_VB the_DT foremost_JJ priority_NN of_IN both_DT investigator_NN and_CC
        institution_NN ._.
        This_DT narrow_JJ window_NN avoids_VBZ absolute_JJ prohibition_NN while_IN striving_VBG to_TO prevent_VB institutional_JJ
        participation_NN where_WRB credible_JJ alternatives_NNS exist_VBP ._. Only_RB by_IN such_JJ stringent_JJ self-policing_JJ can_MD
        we_PRP sustain_VB the_DT trustworthiness_NNS and_CC credibility_NN of_IN biomedical_JJ research_NN ,_, researchers_NNS ,_, and_CC
        their_PRP$ institutions_NNS ,_, while_IN continuing_VBG vigorously_RB to_TO promote_VB the_DT translation_NN of_IN biomedical_JJ
        discovery_NN for_IN the_DT public_NN 's_POS benefit_NN ._.
      
      
        Ross_NNP McKinney_NNP 's_POS Response_NNP to_TO David_NNP Korn_NNP 's_POS Viewpoint_NN
        The_DT public_NN has_VBZ every_DT right_NN to_TO expect_VB that_IN academic_JJ institutions_NNS are_VBP working_VBG first_JJ for_IN
        the_DT public_NN 's_POS interest_NN ._. This_DT value_NN is_VBZ even_RB codified_VBN in_IN the_DT laws_NNS granting_VBG these_DT institutions_NNS
        tax-exempt_JJ status_NN ._. The_DT public_NN also_RB expects_VBZ that_IN new_JJ ,_, more_RBR effective_JJ therapies_NNS will_MD be_VB
        developed_VBN swiftly_RB as_IN a_DT consequence_NN of_IN its_PRP$ support_NN for_IN academic_JJ research_NN ._.
        The_DT inventor_NN of_IN a_DT new_JJ technology_NN is_VBZ always_RB more_RBR motivated_JJ to_TO see_VB it_PRP through_IN to_TO
        widespread_JJ use_NN than_IN anyone_NN else_RB ._. This_DT motivation_NN ,_, which_WDT may_MD be_VB as_IN simple_JJ and_CC benign_JJ as_IN
        curiosity_NN or_CC as_IN easy_JJ to_TO understand_VB as_IN a_DT financial_JJ incentive_NN ,_, is_VBZ a_DT powerful_JJ force_NN driving_VBG
        human_JJ research_NN ._. This_DT force_NN can_MD be_VB disciplined_VBN and_CC controlled_VBN by_IN the_DT IRB_NNP and_CC policies_NNS on_IN
        conflicts_NNS of_IN interest_NN ._. Personal_JJ investment_NN in_IN research_NN is_VBZ ,_, nevertheless_RB ,_, an_DT important_JJ
        driver_NN of_IN scientific_JJ progress_NN ._.
        When_WRB society_NN makes_VBZ an_DT unnecessarily_RB broad_JJ assumption_NN that_IN nearly_RB all_DT research_NN with_IN
        financial_JJ implications_NNS for_IN investigators_NNS or_CC their_PRP$ institution_NN is_VBZ potentially_RB corrupted_JJ ,_, a_DT
        brake_NN is_VBZ placed_VBN on_IN progress_NN ._. Society_NNP will_MD be_VB better_JJR served_VBN by_IN establishing_VBG clear_JJ guidelines_NNS
        and_CC formalizing_VBG oversight_NN of_IN the_DT research_NN process_NN than_IN by_IN rigidly_RB limiting_VBG clinical_JJ
        research_NN affected_VBN by_IN conflict_NN of_IN interest_NN ._. As_IN examples_NNS ,_, clinical_JJ trials_NNS should_MD have_VB
        independent_JJ data_NNS safety_NN monitoring_VBG boards_NNS charged_VBN to_TO review_VB the_DT study_NN design_NN ,_, execution_NN ,_,
        data_NNS analysis_NN ,_, and_CC publication_NN of_IN results_NNS ._. The_DT IRB_NNP system_NN should_MD be_VB strengthened_VBN in_IN its_PRP$
        independence_NN through_IN the_DT use_NN of_IN community_NN members_NNS ._. And_CC ,_, to_TO be_VB certain_JJ that_IN institutional_JJ
        conflict_NN of_IN interest_NN is_VBZ avoided_VBN ,_, an_DT IRB_NNP from_IN outside_IN the_DT institution_NN in_IN most_JJS cases_NNS will_MD be_VB
        preferable_JJ
        Society_NNP wants_VBZ better_JJR treatments_NNS ._. The_DT fact_NN that_IN an_DT inventor_NN has_VBZ mixed_VBN motives_NNS for_IN
        developing_VBG a_DT new_JJ treatment_NN has_VBZ always_RB been_VBN acknowledged_VBN ._. The_DT need_VBP to_TO carefully_RB manage_VB the_DT
        experimental_JJ process_NN in_IN human_JJ studies_NNS has_VBZ always_RB been_VBN understood_VBN ._. However_RB ,_, when_WRB rules_NNS
        minimize_VB the_DT role_NN of_IN inventors_NNS at_IN academic_JJ centers_NNS ,_, by_IN forcing_VBG trials_NNS of_IN their_PRP$ new_JJ ideas_NNS to_TO
        go_VB to_TO outside_JJ institutions_NNS ,_, society_NN loses_VBZ more_JJR than_IN it_PRP gains_VBZ ._. The_DT incremental_JJ gain_NN in_IN
        safety_NN is_VBZ likely_JJ to_TO be_VB small_JJ (_( particularly_RB if_IN oversight_NN is_VBZ well_RB established_VBN )_) ,_, while_IN the_DT
        decrease_NN in_IN speed_NN of_IN development_NN will_MD be_VB significant_JJ ._.
      
      
        David_NNP Korn_NNP 's_POS Response_NNP to_TO Ross_NNP McKinney_NNP 's_POS Viewpoint_NN
        There_EX are_VBP many_JJ similarities_NNS between_IN the_DT position_NN espoused_JJ by_IN Ross_NNP McKinney_NNP and_CC my_PRP$
        position_NN ._. Most_JJS saliently_RB ,_, we_PRP both_DT recognize_VB the_DT critically_RB important_JJ role_NN played_VBN by_IN
        academic_JJ biomedical_JJ scientists_NNS in_IN making_VBG discoveries_NNS and_CC in_IN facilitating_VBG their_PRP$ efficient_JJ
        translation_NN into_IN beneficial_JJ products_NNS ._. Neither_DT of_IN us_PRP proposes_VBZ that_IN academic_JJ investigators_NNS ,_,
        or_CC their_PRP$ institutions_NNS ,_, should_MD be_VB flatly_RB prohibited_VBN from_IN trying_VBG to_TO foster_VB that_DT translation_NN
        in_IN the_DT presence_NN of_IN financial_JJ self_NN interests_NNS ._.
        But_CC there_EX is_VBZ an_DT important_JJ difference_NN ._. McKinney_NNP 's_POS approach_NN for_IN dealing_VBG with_IN institutional_JJ
        conflicts_NNS of_IN interest_NN depends_VBZ critically_RB on_IN the_DT engagement_NN of_IN external_JJ agents_NNS to_TO monitor_VB
        closely_RB both_DT scientific_JJ integrity_NN and_CC the_DT welfare_NN of_IN human_JJ participants_NNS ._. That_DT ,_, in_IN my_PRP$ view_NN ,_,
        would_MD require_VB such_JJ deep_JJ interposition_NN of_IN those_DT agents_NNS into_IN the_DT conduct_NN of_IN academic_JJ research_NN
        as_IN to_TO be_VB not_RB only_RB unprecedented_JJ but_CC unfeasible_JJ ._. Beyond_IN that_DT ,_, the_DT approach_NN falls_VBZ short_JJ with_IN
        respect_NN to_TO the_DT maintenance_NN of_IN institutional_JJ trustworthiness_NNS and_CC protection_NN of_IN public_JJ
        trust_NN ._.
        Routine_NNP clinical_JJ assessment_NN of_IN technologies_NNS by_IN financially_RB interested_JJ institutions_NNS
        fosters_NNS public_JJ cynicism_NN and_CC distrust_NN of_IN the_DT motives_NNS of_IN academic_JJ biomedical_JJ researchers_NNS ._. The_DT
        protective_JJ mechanisms_NNS recommended_VBN by_IN McKinney_NNP are_VBP opaque_JJ to_TO the_DT public_NN and_CC reflect_VB a_DT
        “ business_NN as_IN usual_JJ” image_NN that_WDT fails_VBZ fully_RB to_TO account_VB for_IN the_DT markedly_RB changed_VBN
        circumstances_NNS and_CC perceptions_NNS of_IN academic_JJ biomedical_JJ research_NN ._. Most_JJS important_JJ ,_, the_DT
        mechanisms_NNS appear_VBP to_TO be_VB aimed_VBN primarily_RB at_IN protecting_VBG institutions_NNS '_POS financial_JJ
        interests_NNS ._.
        By_IN contrast_NN ,_, the_DT American_NNP Association_NNP of_IN Medical_NNP Colleges_NNS formulation_NN urges_VBZ that_IN any_DT
        institutional_JJ involvement_NN in_IN clinical_JJ research_NN involving_VBG human_JJ participants_NNS in_IN the_DT presence_NN
        of_IN financial_JJ conflicts_NNS must_MD be_VB predicated_VBN on_IN the_DT presence_NN or_CC absence_NN within_IN the_DT institution_NN
        of_IN demonstrably_RB unique_JJ capability_NN ._. This_DT approach_NN offers_VBZ a_DT much_RB higher_JJR and_CC more_RBR credible_JJ
        standard_NN that_WDT aims_VBZ to_TO protect_VB not_RB only_RB participant_NN well-being_NN and_CC scientific_JJ integrity_NN ,_, but_CC
        also_RB institutional_JJ trustworthiness_NNS and_CC public_JJ trust_NN ._.
      
    
  
